[Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].
The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated. open, non-controlled surveillance study conducted at 744 centers. 3,076 patients suffering from bronchitis. 600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose. evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance. impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%). treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.